Excelimmune Raises $1M

2/12/10

Excelimmune, a Woburn, MA developer of human antibody-based therapies, announced that it has raised $1 million in Series B funding from a group of existing and new investors. The funding will go to research for its first drug candidate, Staphguard, designed to treat methicillin-resistant staph infections. Greenheart was the sole investor in Excelimmune’s 2007 Series A round.

By posting a comment, you agree to our terms and conditions.